



## Equillium to Present at Jefferies 2019 Healthcare Conference

May 23, 2019

LA JOLLA, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that Dan Bradbury, Equillium's chairman and chief executive officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019.

**Date:** Wednesday, June 5, 2019

**Time:** 10:00 AM Eastern Time | 7:00 AM Pacific Time

**Location:** Grand Hyatt in New York

A live webcast of the presentation will be available under the "Investors" section of the Company's website at <https://ir.equilliumbio.com/>. Replays will be available for 30 days following each webcast.

### About Equillium

Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need.

Equillium's initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Equillium believes that itolizumab has the potential to be a best-in-class disease modifying therapeutic and is advancing itolizumab into clinical development in multiple immuno-inflammatory indications with high unmet medical need. For more information, visit [www.equilliumbio.com](http://www.equilliumbio.com).

### Investor Contact

+1-858-412-5302

[ir@equilliumbio.com](mailto:ir@equilliumbio.com)

### Media Contact

Heidi Chokeir, Ph.D.

Canale Communications

+1-619-203-5391

[heidi@canalecomm.com](mailto:heidi@canalecomm.com)